Loren Miller
Infectious Disease · Torrance, CANPI 1346286606
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Merck at 29.7% of the total.
Across 154 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$897
- Shionogi Inc$761
- Paratek Pharmaceuticals, Inc.$468
- Viiv Healthcare Company$290
- Melinta Therapeutics, LLC$158
- AbbVie$123
- plus $325 from 8 others
Across 95 payments — averaging $42,865 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Paratek Pharmaceuticals, Inc.$2.9M
- Merck$554K
- Genentech, Inc.$303K
- Regeneron$173K
- Astellas Pharma Global Development$109K
- GSK$55K
What the payments were for
- Food & beverage$2,78592%
- Education$2378%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 49 | $897 |
| Shionogi Inc | 45 | $761 |
| Paratek Pharmaceuticals, Inc. | 17 | $468 |
| Viiv Healthcare Company | 13 | $290 |
| Melinta Therapeutics, LLC | 9 | $158 |
| AbbVie(2 entities) | 8 | $123 |
| Astellas Pharma US Inc | 3 | $94 |
| Gilead | 2 | $56 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $45 |
| Medline Industries LP | 1 | $44 |
| Mylan Specialty L.p. | 2 | $29 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| Pfizer | 1 | $19 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$113
How this compares
$3,022 in reported general payments places this provider in the 75th percentile of 856 infectious disease providers in California.
Other infectious disease in Torrance
- James McKinnellTorrance$762K
- Behzad NoorianTorrance$120K
- Eric DaarTorrance$72K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.